Long-acting reversible contraception

US trade name (manufacturer)	Progestin (mg)*	Estrogen (micrograms)^¶
Depo-Provera intramuscular (Pfizer)	Medroxyprogesterone acetate (150 mg/mL)	None
Depo-SubQ Provera 104 subcutaneous (Pfizer)	Medroxyprogesterone acetate (104 mg/0.65 mL)	None
Liletta 52 mg intrauterine device (Actavis)	Levonorgestrel (releases 0.0186 mg/day, decreasing to approximately 0.0163 mg/day at 1 year, then decreasing to approximately 0.0143 mg/day at 2 years, and 0.0126 mg/day at 3 years)	None
Mirena 52 mg intrauterine device (Bayer)	Levonorgestrel (releases approximately 0.02 mg/day, decreasing progressively to 0.01 mg/day by 5 years)^Δ	None
Skyla 13.5 mg intrauterine device (Bayer)	Levonorgestrel (releases 0.014 mg/day, decreasing to approximately 0.01 mg/day after 60 days, then decreasing to approximately 0.005 mg/day after 3 years)	None
Nexplanon 68 mg subdermal implant (Organon)^◊	Etonogestrel (releases 0.06 to 0.07 mg/day in weeks 5 to 6, decreasing to approximately 0.035 to 0.045 mg/day by 1 year, then decreasing to approximately 0.03 to 0.04 mg/day by year 2, and then to 0.025 to 0.03 mg/day by end of year 3)	None

* Different progestins are not equivalent on a milligram basis.
¶ Ethinyl estradiol and mestranol are not equivalent on a milligram basis; the results of some studies indicate that 30 to 35 mcg of ethinyl estradiol is equivalent to 50 mcg of mestranol.
Δ Decreases to 0.01 mg/day by 5 years. Do not leave same system in place for >5 years.
◊ Also contains radiopaque (barium sulfate 15 mg).

Adapted with special permission from The Medical Letter on Drugs and Therapeutics, September 14, 2015; Vol. 57 (1477):e133-e134. www.medicalletter.org.
Additional data from:

US Food & Drug Administration Orange Book: Approved Drugs with Therapeutic Equivalence Equations. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm (Accessed on September 30, 2015).

Graphic 104648 Version 8.0

خرید پکیج

Long-acting reversible contraception